According to a recent study, in patients with frontotemporal dementia (FTD), epileptic seizures are significantly more common ...

Paradromics Inc. completed its first human procedure with the Connexus BCI, marking a milestone in brain-computer interface ...

The heat can also trigger migraines either directly, by affecting thermoregulatory processes in the brain, or indirectly, by ...

A new study published in the Journal of Ethnopharmacology finds that cannabidiol (CBD) may offer protective and ...

No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies ...

AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the ...

US-based NeuroPace has reported the initial primary endpoint one-year outcomes from the two-year NAUTILUS trial of the RNS ...

NeuroPace announced preliminary one-year results from its clinical study evaluating neuromodulation therapy for generalized ...

NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA ...

NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study ...

"We view the totality of the data in the NAUTILUS study as a meaningful catalyst that adds to the growing body of evidence and momentum in our business,” said Joel Becker, Chief Executive Officer.